Longeveron closes $5 million public offering with warrant potential

Longeveron Inc. (NASDAQ: LGVN) completed a public offering that raised $5 million in gross proceeds before fees and expenses, the clinical-stage biotechnology company announced.

The offering included 5,882,354 shares of Class A common stock and pre-funded warrants at a combined price of $0.85 per share, along with short-term warrants to purchase up to 14,705,885 additional shares. The warrants carry an exercise price of $0.85 per share and remain exercisable for 24 months from issuance.

If all warrants are exercised for cash, the company could receive an additional $12.5 million in gross proceeds, though no assurance exists that warrant holders will exercise their rights.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering. Company board members and insiders participated in the offering under the same terms as other investors.

Longeveron plans to use the net proceeds to fund clinical and regulatory development of its lead product laromestrocel for multiple conditions including hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy. Additional funds will support regulatory approvals, manufacturing activities, capital expenditures, and general corporate purposes.

The securities were offered under a registration statement filed with the Securities and Exchange Commission that became effective August 8, 2025.

Longeveron develops regenerative medicine therapies using mesenchymal stem cells derived from young adult donor bone marrow. The company's laromestrocel therapy has received multiple FDA designations including Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy designations across various programs.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Erasca prices upsized stock offering at $17.50 per share
• Jones Ventures INTL Acquisition1 prices $200M IPO on Nasdaq